Your browser doesn't support javascript.
loading
LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma.
Gur, Chamutal; Wang, Shuang-Yin; Sheban, Fadi; Zada, Mor; Li, Baoguo; Kharouf, Fadi; Peleg, Hagit; Aamar, Suhail; Yalin, Adam; Kirschenbaum, Daniel; Braun-Moscovici, Yolanda; Jaitin, Diego Adhemar; Meir-Salame, Tomer; Hagai, Efrat; Kragesteen, Bjørt K; Avni, Batia; Grisariu, Sigal; Bornstein, Chamutal; Shlomi-Loubaton, Shir; David, Eyal; Shreberk-Hassidim, Rony; Molho-Pessach, Vered; Amar, Dalit; Tzur, Tomer; Kuint, Rottem; Gross, Moshe; Barboy, Oren; Moshe, Adi; Fellus-Alyagor, Liat; Hirsch, Dana; Addadi, Yoseph; Erenfeld, Shlomit; Biton, Moshe; Tzemach, Tehila; Elazary, Anat; Naparstek, Yaakov; Tzemach, Reut; Weiner, Assaf; Giladi, Amir; Balbir-Gurman, Alexandra; Amit, Ido.
Afiliação
  • Gur C; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel; Rheumatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Wang SY; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel. Electronic address: shuangyinwang@me.com.
  • Sheban F; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Zada M; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Li B; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Kharouf F; Rheumatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Peleg H; Rheumatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Aamar S; Rheumatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Yalin A; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Kirschenbaum D; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Braun-Moscovici Y; Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, Haifa, Israel.
  • Jaitin DA; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Meir-Salame T; Flow Cytometry Unit, Department of Biological Services, Weizmann Institute, Rehovot, Israel.
  • Hagai E; Flow Cytometry Unit, Department of Biological Services, Weizmann Institute, Rehovot, Israel.
  • Kragesteen BK; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Avni B; Department of Bone Marrow Transplantation, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Grisariu S; Department of Bone Marrow Transplantation, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Bornstein C; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Shlomi-Loubaton S; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • David E; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Shreberk-Hassidim R; Dermatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Molho-Pessach V; Dermatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Amar D; Plastic Surgery Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Tzur T; Plastic Surgery Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Kuint R; Institue of Pulmonology Medicine, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Gross M; Orthopedic Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Barboy O; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Moshe A; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Fellus-Alyagor L; The Department of Veterinary Resources, Weizmann Institute, Rehovot, Israel.
  • Hirsch D; The Department of Veterinary Resources, Weizmann Institute, Rehovot, Israel.
  • Addadi Y; Life Sciences Core Facilities, Weizmann Institute, Rehovot, Israel.
  • Erenfeld S; Department of Bone Marrow Transplantation, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Biton M; Department of Biological Regulation, Weizmann Institute, Rehovot, Israel.
  • Tzemach T; Rheumatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Elazary A; Rheumatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Naparstek Y; Rheumatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Tzemach R; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel; Rheumatology Institute at the Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel.
  • Weiner A; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Giladi A; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel.
  • Balbir-Gurman A; Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, Haifa, Israel.
  • Amit I; Department of Systems Immunology, Weizmann Institute, Rehovot, Israel. Electronic address: ido.amit@weizmann.ac.il.
Cell ; 185(8): 1373-1388.e20, 2022 04 14.
Article em En | MEDLINE | ID: mdl-35381199
ABSTRACT
Systemic sclerosis (scleroderma, SSc) is an incurable autoimmune disease with high morbidity and mortality rates. Here, we conducted a population-scale single-cell genomic analysis of skin and blood samples of 56 healthy controls and 97 SSc patients at different stages of the disease. We found immune compartment dysfunction only in a specific subtype of diffuse SSc patients but global dysregulation of the stromal compartment, particularly in a previously undefined subset of LGR5+-scleroderma-associated fibroblasts (ScAFs). ScAFs are perturbed morphologically and molecularly in SSc patients. Single-cell multiome profiling of stromal cells revealed ScAF-specific markers, pathways, regulatory elements, and transcription factors underlining disease development. Systematic analysis of these molecular features with clinical metadata associates specific ScAF targets with disease pathogenesis and SSc clinical traits. Our high-resolution atlas of the sclerodermatous skin spectrum will enable a paradigm shift in the understanding of SSc disease and facilitate the development of biomarkers and therapeutic strategies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico Limite: Humans Idioma: En Revista: Cell Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico Limite: Humans Idioma: En Revista: Cell Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Israel